Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Medical Oncology|September 2, 2016
Concepts and targets in triple-negative breast cancer: recent results and clinical implicationsPoornima Saha, Rita Nanda
Current Treatment Options in Oncology|October 28, 2024
Updates in Breast Cancer Screening and DiagnosisGeorgia Spear, Kyla Lee, Allison DePersia, et al.
JAMA Network Open|February 3, 2026
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER TrialJincong Q Freeman, Poornima Saha, Daniel S Peiffer, et al.
NPJ Breast Cancer|June 15, 2024
Development and validation of a clinical breast cancer tool for accurate prediction of recurrenceAsim Dhungana, Augustin Vannier, Fangyuan Zhao, et al.
Breast Cancer Research and Treatment|November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltrationMargarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
Breast Cancer Research and Treatment|February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancerNan Chen, Margarite Matossian, Poornima Saha, et al.
Human Gene Therapy|May 13, 2020
LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse ModelsWeidong Xu, Yuefeng Yang, Zebin Hu, et al.
Breast Cancer Research and Treatment|August 8, 2025
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancerErica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, et al.
JCO Global Oncology|May 29, 2026
Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource SettingsRubem Jose Peres Moreira, Jose Bines, Asim Dhungana, et al.
Springerplus|July 8, 2016
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerRita Nanda, Erica M Stringer-Reasor, Poornima Saha, et al.
Pageof 2